Corporate News Update: Relmada Therapeutics and Peer Performance

Relmada Therapeutics (ticker RLMD) experienced a notable uptick in its share price during a 24‑hour window that concluded at 11:20 AM Central Europe on Wednesday, 21 March 2026. The stock advanced 6.33 %, bringing its trading price to approximately USD 3.36 on major exchanges. With a circulating supply of 106.7 million shares, the company’s market capitalisation stands at USD 337.1 million, a figure that reflects the current valuation derived from the latest closing price.

Trading Activity and Historical Context

In the preceding 24 hours, roughly USD 2.5 million worth of Relmada shares were exchanged, a modest volume that underscores the company’s position as a mid‑cap entity in the specialty pharmaceutical sector. Over the past month, however, the stock has traded down 19.23 %, signalling a broader decline in investor sentiment or sector‑specific challenges. The simple moving average of the last 200 trading days is USD 5.39, a benchmark that indicates the current price is below the medium‑term trend. Relmada’s 52‑week high of USD 8.00 was recorded on 5 June 2026, while its lowest price in the same period was USD 2.02 on 23 October 2025, illustrating a relatively wide price range over the last year.

Comparative Performance of Peer Companies

The recent market activity also affected several peers in the broader biopharmaceutical and medical technology landscape:

  • Strata Critical Medical (SRTA): Shares rose 3.3 % to USD 4.69, with a market capitalisation of USD 401.6 million.
  • Natural Gas Services (NGS): Shares declined 0.52 % to USD 30.88, maintaining a market capitalisation of USD 400.4 million and a price‑to‑earnings ratio of 19.29.
  • Oxford Industries (OXM): Shares increased 1.09 % to USD 26.92, with a market capitalisation of USD 398.9 million.
  • Avita Medical (RCEL): Shares remained flat at USD 13.80, with a market capitalisation of USD 403.3 million.
  • Myriad Genetics (MYGN): Shares surged 31.59 % to USD 5.54, achieving a market capitalisation of USD 402.7 million. This significant rise follows the announcement that Myriad has entered into a definitive agreement to sell its Prenatal Health testing business to Labcorp. The transaction, valued at $210 million in cash plus inventory, includes several key tests and is part of a strategic portfolio review aimed at strengthening Myriad’s balance sheet. The deal is expected to close in early 2027, pending regulatory approval, and may have a notable impact on Myriad’s revenue growth and profitability in the first year following completion.

Relmada Therapeutics: Company Overview

Relmada Therapeutics, Inc. is a clinical‑stage specialty pharmaceutical company headquartered in New York, United States, and listed on the Nasdaq exchange. The firm focuses on developing and commercialising established drug products, with a particular emphasis on pain management therapeutics. Relmada is actively engaged in research and acquisition of chemical entities that may enhance its therapeutic pipeline. For further information on the company’s clinical programmes, corporate strategy, and financial performance, interested parties can visit the official website at www.relmada.com .

This article synthesises the latest market movements, historical performance metrics, and corporate developments pertinent to Relmada Therapeutics and its industry peers. All figures are accurate as of the closing time specified and are presented to aid investors and stakeholders in contextualising recent trading activity.